Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors Review

   


Authors: Grosser, R.; Cherkassky, L.; Chintala, N.; Adusumilli, P. S.
Review Title: Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors
Abstract: Checkpoint blockade (CPB) therapy can elicit durable clinical responses by reactivating an exhausted immune response. However, response rates remain limited, likely secondary to a lack of a tumor-reactive immune infiltrate. Chimeric antigen receptor (CAR) T cells may provide the necessary tumor-targeting immune infiltrate and a highly specific antitumor immune response. This can be further amplified by the addition of CPB agents, which serve to counteract the immune inhibitory environment undermining optimal CAR T cell efficacy. Herein, we review preclinical and clinical combination therapy with CAR T cells and CPB agents, with a focus on solid tumor malignancies. © 2019 Elsevier Inc.
Keywords: immunotherapy; chimeric antigen receptor; pd-1; checkpoint blockade; car t cell
Journal Title: Cancer Cell
Volume: 36
Issue: 5
ISSN: 1535-6108
Publisher: Cell Press  
Date Published: 2019-11-11
Start Page: 471
End Page: 482
Language: English
DOI: 10.1016/j.ccell.2019.09.006
PUBMED: 31715131
PROVIDER: scopus
PMCID: PMC7171534
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85074446399&doi=10.1016%2fj.ccell.2019.09.006&partnerID=40&md5=b421114cdba4f374d6a52d7118e963c6
Notes: Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Prasad S Adusumilli
    497 Adusumilli
  2. Leonid Cherkassky
    14 Cherkassky
  3. Rachel Grosser
    9 Grosser
  4. Navin Kumar Chintala
    27 Chintala
Related MSK Work